Anaplastic carcinoma of the thyroid (ATC) is a lethal human malignant cancer with median survival of 6 months. To date, no treatment has substantially changed its course, which makes urgent the need for development of novel drugs or novel formulations for drug delivery. Nanomedicine has enormous potential to improve the accuracy of cancer therapy by enhancing availability and stability, decreasing effective doses and reducing side effects of drugs.
Introduction
Thyroid cancers are the most common tumors of endocrine origin and their incidence has increased globally over the past 10 years (Jemal et al., 2011) . They derive from follicular and para-follicular cells and most of them are differentiated papillary and follicular carcinomas, while 1% of cases are partly differentiated or undifferentiated and classified as anaplastic thyroid carcinoma (ATC). Most differentiated carcinomas display slow progression and are effectively treated with thyroidectomy and radioiodine ablation (Broecker-Preuss et al., 2015) . By contrast, ATC progression is extremely rapid and no effective systemic therapy has been established so that the overall survival level is only 13% (Gilliland et al., 1997) . At time of diagnosis, ATC often display an advanced stage of development, local invasion of the trachea, esophagus, blood vessels and muscles, and development of distant metastases to the mediastinum, lung, liver, bone and brain (Phay et al., 2013; Chen et al., 2014; Mirrielees et al., 2014; Varinot et al., 2014) . Risk factors of thyroid cancers include environmental and genetic factors, exposure to ionizing radiation, and pre-existing thyroid neoplasia (Campanella et al., 2014) . Genetic alterations that contribute to thyroid carcinoma include point mutations of BRAF and RAS (Fukushima & Takenoshita, 2005; Marotta et al., 2011);  translocations involving RET/PTC1, RET/PTC3 and PAX8/PPAR-γ (Romei & Elisei, 2012; Raman & Koenig, 2014) , and alterations of the DNA methylation pattern (Ragazzi et al., 2014; Faam et al., 2015) .
To date, no effective therapies are available for ATC, which are currently treated with trivalent therapies including surgery, chemotherapy and radiotherapy resulting in an increased median survival of only 5 months (Wein & Weber, 2011; Parenti et al., 2014) .
Camptothecin (CPT) is a pentacyclic alkaloid isolated from the bark of Campotheca Acuminata, (Wall et al., 1996) . It quickly enters into cells and exerts anti-tumor activity by blocking topoisomerase-1 (TOP-1) in a specific and reversible manner. Unfortunately, it is weakly soluble in water and undergoes spontaneous and rapid inactivation at neutral pH by the opening of its six member lactone E ring. Therefore, it requires a prolonged infusion, so that the complex TOP-1 is kept in place long enough to allow the induction of DNA damage (Fassberg & Stella, 1992; Chourpa et al., 1998) . Moreover, its dosage and anti-tumor efficacy are limited by severe side effects, such as severe myelosuppression accompanied by prolonged diarrhea, fever, nausea and vomiting (Basili & Moro, 2009 ). The main water-soluble derivatives of CPT are the Irinotecan (Compostar®) and Topotecan (Hycamtin®).
To overcome problems in administering the drug, we previously investigated the antineoplastic effects of CPT-loaded into nanosponges of β-cyclodextrin (CN-CPT) (Gigliotti et al., 2016a) .
Results showed that CN-CPT increased solubility, was protected from degradation and inhibited the growth of prostate tumor cells both in vitro and in vivo to a higher extent than free CPT.
Cyclodextrin nanosponges are novel biocompatible polymer nanoparticles obtained by cross-linking of cyclodextrins (Subramanian et al., 2012) , which are cyclic oligosaccharides consisting of multiple α-D-glucopyranose units linked together by an α-1.4 bond and include α, β and γ cyclodextrins carrying six, seven or eight glucopyranose units, respectively. β-cyclodextrin is the most widely used for nanosponge production because of its high capability to encapsulate drugs (Torne et al., 2013; Trotta et al., 2014) .
The aim of this study was to extend that work by assessing the CN-CPT effectiveness on ATC both in vitro and in vivo. Results showed that CN-CPT inhibited the growth of ATC cell lines both in vitro and in vivo to a higher extent than free CPT. Moreover, it inhibited tumor cell adhesion to endothelial cells and migration which suggest that it may be effective also to inhibit tumor metastatic dissemination.
Methods

Materials
CPT was purchased from Sigma-Aldrich (Sigma-Aldrich, St Louis, MO, USA). β-Cyclodextrins (β-CDs) were a gift from Roquette (France). CD nanosponges (CNs) cross-linked at 1:4 molar ratio with carbonyldiimidazole were prepared as described previously (Swaminathan et al., 2010) . All reagents were of analytical grade. Laboratory reagents were from Sigma-Aldrich unless otherwise specified. Cell culture reagents were purchased from Gibco/Invitrogen (Life Technologies, Paisley, UK) except where otherwise indicated.
Preparation of CPT in solution and camptothecin-loaded nanosponges (CN-CPT)
To prepare the CPT solution, about 1 mg of CPT was dissolved in 1 mL of dimethylsulfoxide (DMSO): water mixture (1:1, w/w) at pH = 5.5. A further dilution was carried out using 0.9 % NaCl solution at pH = 5.5 containing 30 % of DMSO.
To load CPT in CNs, 4 mg of CPT were added to an aqueous suspension of CNs in a ratio of 1:4 (drug to CN by weight) at pH 5.5 and stirred for 24 h in the dark. The aqueous suspension was then centrifuged at 8000 rpm for 10 min to separate the free drug, not incorporated, as a solid residue below the colloidal supernatant. The colloidal supernatant was freeze-dried to obtain drug-loaded nanosponges as a powder. This powder can be stored at 4 °C until use.
A weighed amount of freeze-dried CN-CPT was dispersed in a sterile aqueous solution at pH 6.0 containing 0.9 % NaCl and 3% polyethylene glycol (PEG)-400 w/v under stirring to obtain an isotonic aqueous nanosuspension containing 100 µg·mL -1 of CPT for the in vivo administration. For the free CPT formulation, a weighed amount of CPT was dissolved in a DMSO: water mixture (1:1, w/w) at pH = 5.5 and then diluted with a sterile aqueous solution at pH 6.0 containing 0.9 % NaCl and 3 % PEG-400 w/v to obtain a 100 µg·mL -1 concentration. The quantitative determination of CPT concentration in the formulations was evaluated by HPLC (Swaminathan et al., 2010) .
CN-CPT sizes and polydispersity indices were measured by dynamic light scattering using a 90
Plus particle sizer (Brookhaven Instruments Corporation, USA) equipped with MAS OPTION particle sizing software. The measurements were made at a fixed angle of 90 ° for all samples. The samples were suitably diluted with filtered distilled water for every measurement. Zeta potential measurement was then carried out using an additional electrode in the same instrument. For zeta potential determination, samples were diluted with 0.1 mM KCl and placed in the electrophoretic cell, where an electric field of about 15 V/cm was applied.
The in vitro release was carried out using multi-compartment rotating cells with a dialysis membrane (Sartorius, cut off 12,000 Da). The donor phase consisted of CPT-nanosponge formulation in phosphate buffer at pH 7.4 (1 ml). The receiving phase consisted of phosphate buffer, pH 7.4. The receiving phase was completely withdrawn and replaced with fresh medium after fixed time intervals, suitably diluted and analyzed using the HPLC method described before.
CN-CPT showed an average diameter of about 350 nm, a polydispersity index of 0.11 and a negative surface charge with a zeta potential value of -27.4 mV. The in vitro release kinetics of CPT from nanosponge formulation was slow and prolonged over time, reaching 15.5 % after 24 h. 
Cells
Cell adhesion assay
HUVEC were grown to confluence in 24-well plates. Then, they were pre-treated with increasing concentrations of CPT or CN-CPT (10 -11 -10 -8 M) for 24 h and washed twice with fresh medium. The tumor cells (1x10 5 cells/well) were seeded and left to adhere with HUVEC for 1 h, as previously reported (Minelli et al., 2012a; Minelli et al., 2012b) . (mean±SEM) (Dianzani et al., 2010) .
Cell motility assay
In the wound healing assay, after starvation for 18-24 h in serum free medium, cells were plated onto six-well plates (10 6 cell/well) and grown to confluence. Cell monolayers were wounded by scratching with a pipette tip along the diameter of the well, and they were washed twice with serumfree medium before their incubation with culture medium in the absence or presence of CPT or CN-CPT (10 -8 M) and mitomycin C (50 μg·mL -1 , Sigma-Aldrich). In order to monitor cell movement into the wounded area, five fields of each wound were photographed immediately after the scratch (0 h) and after 24 h (Gigliotti et al., 2016a; Dianzani et al., 2014) .
In the Boyden chamber (BD Biosciences, San Jose, CA, USA) invasion assay, cells (8000) Absorbance was detected with a microplate reader (Bio-Rad Laboratories), and the Excel program was used to calculate the standard curve.
Protein extraction and Western blot analysis
Cells were seeded into six-well plates and treated for 48 h with CPT or CN-CPT (10 -8 -10 -9 M). CPT and CN-CPT were replenished every 24 h (48 h culture: 24 + 24 h) without changing the culture medium. Cells were then lysed in a buffer composed of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% sodium deoxycholate, 1% Nonidet P-40, phosphatase and a protease inhibitor cocktail. Cell lysates were cleared from insoluble fractions by high speed centrifugation, and protein concentration was determined with a commercially available kit (Bio Rad Laboratories),
and measured with a spectrophotometer (Jasco Analytical Instruments, Easton, MD, USA). Proteins (40 µg) were loaded on 10% SDS-PAGE gels and transferred onto nitrocellulose membranes after electrophoresis. These were blocked by incubation for 1 h at room temperature with 5% nonfat milk dissolved in TBS-Tween 20. The membranes were then probed overnight with antibodies to β-PIX (AdipoGen International, San Diego, CA, USA), pospho-Erk1,2 (Santa Cruz Biotechnology, Dallas, TX, USA), or β-actin (Sigma-Aldrich) and, after 3 washes, incubated for 1 h with the HRPconjugated secondary antibody (Sigma-Aldrich). Bands were detected by chemiluminescence, and densitometric analysis was performed with the Multi-Analyst software (version 1.1, Bio-Rad Laboratories). Annexin V staining and caspase-3 activity Cells (1.5x10 5 ) were treated with CPT or CN-CPT as reported above. After 48 h, they were stained with annexin V using the Annexin V Fluos kit (Beckton Dickinson) and analyzed by flow cytometry. Live cells were those not displaying shrunken/hypergranular morphology and unstained by Annexin V. Caspase-3 activity was assessed in cell lysates using a fluorimetric assay (MBL, Watertown, MA, USA) following the manufacture' instructions.
Cell cycle analysis
In vivo animal models and tumor growth
Animal studies were performed in accordance with EU and institutional guidelines approved by the Bioethics Committee for Animal Experimentation of the University of Turin, Italy (Prot. No.
4.2/2012) using NOD-SCID IL2Rγ null (NSG; 10/11-week-old female) mice, bred under sterile conditions in our animal facilities. Animals were anesthetized with intramuscular injection of Zoletil® (Zolaxepan and Tiletamina) and Rompun® (Xylazina). CAL62 cells were harvested from subconfluent cultures by trypsinization and washed in PBS. Then, cells (10 6 cells in 10 µl) were injected into the right thyroid lobe under surgical sterile conditions and tumors were allowed to grow during the following 10 days. Mice were then randomized into three groups receiving twice weekly intravenous injection of PBS (control group, n=5) or 1 mg·kg -1 CPT (n=7) or 1 mg·kg -1 CN-CPT (n=7).
Mice were weighed twice weekly and sacrificed when the animals appeared moribund. Tumor growth velocity (Tv) was determined using the formula: Tv = V / days from cells injection to excision.
Tumors and lungs were fixed in 10% formalin and paraffin embedded. Four serial sections/tumor were obtained and processed for immunohistochemistry using an automated slide processing platform (Ventana BenchMark XT AutoStainer, Roche) and a mouse monoclonal anti-human Ki-67
(Clone MIB-1) or a rabbit polyclonal anti-mouse CD31 (Abcam, Cambridge, UK) antibodies.
Sections of lungs were stained with Hematoxylin and Eosin (H&E).
Ki-67 positive cells were heterogeneously distributed throughout the tumor. The Ki67 labeled nuclei were evaluated in the tumor areas where these markers were predominant (hot spots) using a digital camera (Olympus Q-colour 3) with area-based image analysis software (Dot-Slide 1.2 version). Ki-67 expression was calculated as the ratio between the labeled and the total nuclear areas. Only nuclei with a strongly positive label were counted. The ten fields with the highest density of positive nuclei were captured. A mean of 3,000 tumor cells per case (range, 2,000-3,800) was counted. Tumor microvessel density (TMD) was measured by evaluating the CD31-positive area and total tumor area per field upon after slide scan of the immunostaining as previously described (Gigliotti et al., 2016a; Passaro et al., 2016) .
Data analysis
Data are shown as mean±standard error of the mean (SEM). Statistical analyses were performed with GraphPad Prism 5.0 software (San Diego, CA, USA). For the in vivo experiments, the results are expressed as the median with interquartile range. One way ANOVA was performed, followed by Tukey's multiple comparison post-test when needed. Kaplan-Mayer survival curves were evaluated with the Log Rank Mantel-Cox test. Only P values < 0.05 were considered to be significant.
Results
CN-CPT inhibits cell proliferation in vitro
We compared the ability of CN-CPT and free CPT to inhibit the growth of BHT-101 and CAL-62 in vitro. Cells were cultured in the presence and absence of titrated amounts (2x10 -10 -2x10 -8 M) of each compound for 24-48 h and the amount of viable cells was then assessed by the MTT assay. Figure 1 shows that CN-CPT inhibited the growth of both cell lines to a higher extent than CPT.
The effect was concentration-and time-dependent with small differences between the two cell lines.
The different effect of the two compounds was detectable in terms of timing, maximal inhibition, and effective doses.
To validate these findings, we performed clonogenic survival assays. Cells were seeded onto 6-well plates and treated with titrated doses (10 -10 -10 -8 ) of each compound. The culture medium was changed after 72 h, and cells were cultured for 10 additional days in the absence of the compounds.
Results showed that treatment with CN-CPT inhibited the ability to form colonies of both cell lines to a higher extent than CPT (supporting information, Figure S1 ). The effect was concentrationdependent with small differences between the two cell lines. The different effect of the two compounds was detectable in terms of effective doses but not in terms of maximal inhibition that was similar at the highest dose.
To assess whether inhibition of cell proliferation induced by CN-CPT affected cell cycle progression, we analyzed the cell cycle in CAL-62 and BHT-101 cells cultured in the presence and absence of titrated amounts of CN-CPT or CPT (10 -9 and 10 -8 M) for 48 h. Results showed that both doses of CN-CPT induced a substantial accumulation of cells in S phase compared to the untreated control in both cell lines. This effect was exerted also by CPT but only at the highest dose ( Figure   2 ).
To assess whether inhibition of cell proliferation induced by CN-CPT involved cell death, we analyzed Annexin V staining, detecting both apoptotic and necrotic cells, and caspase 3 activation, detecting apoptosis, in CAL-62 and BHT-101 cells cultured in the presence and absence of titrated amounts (10 -9 and 10 -8 M) of CN-CPT or CPT for 48 h. Results showed that CN-CPT induced higher Annexin V staining and caspase 3 activation than CPT in both cells lines (Figure 3 ).
CN-CPT inhibits cell adhesion and migration in vitro
Adhesion of tumor cells to the vascular endothelium and their release into the bloodstream is a key step for metastasis formation (Ma & Waxman, 2008) . Therefore, we performed in vitro experiments comparing the effect of CN-CPT and CPT on adhesion to HUVEC and motility of tumor cells.
In the adhesion experiments, HUVEC were pretreated for 24 h with titrated doses (10 -11 and 10 -8 M)
of CN-CPT and CPT, washed, and used for adhesion assays with CAL-62 and BHT-101 cells.
Results showed that CN-CPT inhibited adhesion of both cell lines at higher levels than CPT. The effect was concentration-dependent with small differences between the two cell lines. The different effect of the two compounds was detectable in terms of both effective doses and maximal inhibition (Figure 4 A-B) . The difference was not due to an effect on cell viability since cells were still alive after the 24 h incubation with the drug.
Cell motility was initially assessed using a wound healing assay evaluating cell random migration.
A linear scratch was done in confluent monolayers of CAL-62 and BHT-101 cells, which were then cultured in FCS-free medium to minimize cell proliferation in the presence or absence of CN-CPT and CPT (10 -8 M). Analysis of the cell ability to migrate into the scratch after 24 h showed that CN-CPT inhibited adhesion of both cell lines at higher levels than CPT (supporting information, Figure   S2 ). Then, cell motility was assessed using a Boyden chamber assay assessing directional migration of cells. CAL-62 and BHT-101 cells were seeded in the upper chamber of a Boyden chamber in serum-free medium in the presence or absence of titrated doses (2x10 -9 and 2x10 -8 M) of CN-CPT and CPT and allowed to migrate for 24 h toward the lower chamber containing medium with and without 20% FCS, used as a chemoattractant. Results showed that CN-CPT inhibited cell migration at higher levels than CPT in both cell lines (Figure 4 C-D) . The CN-CPT effect was concentration-dependent with small differences between the two cell lines, whereas CPT displayed some effect on CAL-62 cells but it was almost ineffective on BHT-101 cells.
In both migration assays, doses and timing of treatments minimized the possible confounding effects due to the drug effect on cell growth.
CN-CPT inhibits VEGF-a and IL-8 secretion in vitro.
Since ATC cells express high levels of pro-angiogenic molecules ( Figure S3 ). No differences were found for Angiopoietin 2 secretion (data not shown).
CN-CPT inhibits β-PIX expression and ERK 1,2 phosphorylation in vitro
In order to investigate the mechanisms underlying CN-CPT mediated inhibition of cell proliferation, adhesion, and migration, we evaluated the effect of the drug on expression of β-PIX, involved in rearrangement of the cytoskeleton and cell migration, and on Erk1,2 phosphorylation involved in signaling of multiple surface receptors (Kim et al., 2013; Occhipinti et al., 2013; Dianzani et al., 2014; Stevens et al., 2014; Gigliotti et al., 2016b) . CAL-62 and BHT-101 cells were incubated with titrated doses (10 -9 and 10 -8 M) of CN-CPT or CPT for 48 h, lysed, and analyzed for β-PIX expression and Erk1,2 phosphorylation by Western blot. Results showed that CN-CPT inhibited β-PIX expression and Erk1,2 phosphorylation at higher levels than CPT in both cell lines ( Figure 5 ).
In vivo studies
We compared the effect of CN-CPT and CPT tumor growth and metastatic dissemination in NSG mice injected orthotopically in the thyroid lobe with CAL-62 cells and treated 10 days later with twice weekly injections of PBS, CPT or CN-CPT in the tail vein. Results showed that the overall survival of mice treated with CN-CPT was higher than that displayed by mice injected with either PBS or CPT ( Figure 6A ). In particular, median survivals of mice treated with PBS, CPT and CN-CPT were 28, 25 and 38 days, respectively. The difference of survival between the CN-CPT group and the control group was significant (P = 0.0422, log-rank test).
Analysis of tumor growth velocity showed that CN-CPT significantly inhibited the growth velocity of orthotopic anaplastic thyroid carcinoma xenografts compared to the control group, whereas CPT had no effect ( Figure 6B ).
Analysis of lung metastases showed that CN-CPT significantly inhibited development metastases compared to the control group whereas CPT had no effect ( Figure 6C ).
Histologic analysis of the primary tumor showed that, in control mice, the tumors displayed diffuse necrosis whereas, in CN-CPT-treated mice, tumors displayed decreased necrosis, and in CPTtreated mice an intermediate picture.
Immunohistochemical staining, performed 34 days after tumor challenge showed that Ki-67 + cells were homogeneously distributed in the tumor mass in PBS-and CPT-treated mice, whereas, they were concentrated at the invasive edge in the peripheral area of the tumor, but rare in the centre of the tumor, in CN-CPT treated mice ( Figure 6D ). This enrichment of Ki67 + cells was detected also at 51 days after tumor challenge ( Figure 6E ). To assess the effects on tumor angiogenesis, we stained the tumor sections for CD31 and evaluated the TMD. Results
showed that treatment with CN-CPT substantially decreased the TMD compared with untreated mice and CPT-treated mice, whereas CPT had no effect (Figure 6 F) .
All treatments were well tolerated by the animals without significant weight loss in any group.
Discussion
ATC is a highly aggressive tumor with a poor prognosis and the long-term survival is extremely rare. To date, available therapies do not significantly improve the survival of patients and have only a palliative effect (Patel & Shaha, 2006; Cornett et al., 2007) .
CPT belongs to the drug category of inhibitors of DNA TOP-1 by specifically blocking TOP-1 during the cleavage reaction of DNA and preventing repair of the single-strand breaks. This effect produces blocking of cells in the S phase of the cell cycle, conversion of DNA breaks from single to double helix and death of cells by apoptosis (Huang et al., 2000; Desai et al., 2001; Minelli et al., 2012a) . Several studies demonstrated CPT activity in tumors of various origins, but CPT did not reach clinical use because of its numerous side effects. Moreover, its use is restricted by poor solubility and stability at physiological pH, at which CPT undergoes spontaneous inactivation due to opening of the E ring, decreased bioavailability and enhanced side effects. Several strategies have been described to improve the CPT activity and to decrease the side effects in several type of cancers (Acevedo-Morantes et al., 2013; Xie et al., 2016; Yang et al., 2016) .
Previously, we have reported that CN-CPT displays increased solubility, is protected from degradation and displays an enhanced inhibitory effect on prostate tumor cells both in vitro and in vivo (Fassberg & Stella, 1992; Chourpa et al., 1998; Minelli et al., 2012a; Minelli et al., 2012b; Gigliotti et al., 2016a ).
This work extends those observations to ATC showing that CN-CPT displays increased inhibitory effects in vitro on cell proliferation, as assessed by the MTT and clonogenic assay, and increased ability to block the cell cycle into the S phases and to induce apoptosis. These effects may be ascribable to the inhibitory activity of CPT on TOP1. Moreover, a role may be played also by inhibition of ERK 1,2 phosphorylation since constitutive activation of MAPK signalling is involved in cell survival and proliferation in several cancers, including thyroid cancer (Perri et al., 2015; Lim & Cha, 2011) . It is noteworthy that inhibitors of the MAPK pathway may increase the efficacy of radioiodine therapy in cancer with BRAF mutations (Knauf & Fagin, 2009) .
The in vitro experiments demonstrated that CN-CPT also shows increased ability to inhibit endothelial cells adhesiveness to ATC cells and migration of ATC cells, similarly to what we previously showed for prostate cancer cells. This activity might be related to the ability of CN-CPT to downmodulate expression of β-Pix involved in negative regulation of formation of focal adhesions, which may enhance formation of lamellipodia and cell motility (Kim et al., 2013; Occhipinti et al., 2013; Dianzani et al., 2014; Stevens et al., 2014) .
The in vivo experiments using the SCID xenograft orthotopic model implanted with CAL-62 cells substantially supported these findings since treatment with CN-CPT was more effective than the free drug in improving mice survival and decreasing tumor growth and metastatization at a dose (1 mg·kg -1 ) that did not display any substantial side effects.
Beside the effect on cell proliferation, apoptosis, adhesion and migration, the anti-tumor CN-CPT activity may also involve inhibition of tumor neoangiogenesis as suggested by the CN-CTP ability to inhibit VEGF-a and IL-8 secretion in ATC cells lines in vitro and tumor vascularization in vivo.
We previously showed that CN-CPT, but not free CPT, inhibits proliferation and migration of endothelial cells, proteolytic degradation of the extracellular matrix, and in several in vitro models of angiogenesis, inhibited tumor neoangiogenesis in mouse models of prostate cancer (Gigliotti et al., 2016a) . Solid tumors cannot grow beyond a certain size, generally 1-2 mm 3 , without being supported by tumor neoangiogenesis (Li et al., 2012) , that plays a key role also for metastatic dissemination of cancer cells. Another point is that the higher in vivo activity of CN-CPT compared to free CPT may be partly due to its ability, displayed by most nanoparticles, to accumulate in tumors because of the enhanced permeation and retention effect across the atypical highly fenestrated blood vessels of the tumor (Wang & Thanou, 2010) .
The greater size of the necrotic core detected in the tumors of the control group compared to those of the CN-CPT treated group may be ascribed to the faster growth of the former that may prevent adequate nutrition of the tumor core. The finding that the tumors of CN-CPT treated mice contained a high density of Ki67 + cells at the invasive edge suggests that the anti-proliferative activity of the drug has limited effects in this area of the tumor. However, the CN-CPT effect might be potentiated by combination of CN-CPT with surgery and radiation, since the multimodality approach represents the standard treatment of choice in ATC (Denaro et al., 2013) and the striking CN-CPT effect on tumor metastatization may be crucial to implement the effect of those therapies. The safety (Gigliotti et al., 2016a) and the cheap cost of CN-CPT are also to be considered.
Conclusion
In conclusion, the antineoplastic activity of CN-CPT may result from the combination of the antiproliferative effect associated with the increase of apoptosis in the tumor cells, the inhibition of migration, invasion and metastatization, and, possibly, the inhibition of the neoplastic neovascularisation. Therefore, the anticancer activity of CN-CPT, without evident toxicity, opens up therapeutic perspectives for the ATC, which doesn't respond to conventional therapy.
Translational and clinical studies will ultimately determine the clinical utility and safety of CN-CPT, used alone or in combination with other chemotherapics, as an option for the treatment of this kind of tumor.
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CAL-62
BHT-101 Figure S2 : Effect of CPT and CN-CPT on motility of CAL-62 and BHT-101 cell lines assessed using the wound healing assay. A scratch was made through CAL-62 (A) and BHT-101 (B) cell layer and then cells were cultured in the presence and absence of CPT or CN-CPT for 24 h. Microphotographs of the wounded area were taken immediately after the scratch (0 h) and 24 h later, in order to monitor cell migration into the wounded area (n = 3).
